JP2018519831A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519831A5 JP2018519831A5 JP2017568143A JP2017568143A JP2018519831A5 JP 2018519831 A5 JP2018519831 A5 JP 2018519831A5 JP 2017568143 A JP2017568143 A JP 2017568143A JP 2017568143 A JP2017568143 A JP 2017568143A JP 2018519831 A5 JP2018519831 A5 JP 2018519831A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- unsubstituted
- cancer
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 32
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims 20
- 108091034117 Oligonucleotide Proteins 0.000 claims 18
- 210000004027 cell Anatomy 0.000 claims 17
- 238000012230 antisense oligonucleotides Methods 0.000 claims 13
- 239000000074 antisense oligonucleotide Substances 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 230000028993 immune response Effects 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 125000005647 linker group Chemical group 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 5
- 101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 claims 5
- 125000004474 heteroalkylene group Chemical group 0.000 claims 5
- 230000000638 stimulation Effects 0.000 claims 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000004936 stimulating effect Effects 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 125000000732 arylene group Chemical group 0.000 claims 3
- 125000005549 heteroarylene group Chemical group 0.000 claims 3
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 108010092160 Dactinomycin Proteins 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical group C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims 2
- 229960000640 dactinomycin Drugs 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 claims 1
- 101710168309 CCAAT/enhancer-binding protein alpha Proteins 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 229930192392 Mitomycin Natural products 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 238000007385 chemical modification Methods 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 229960001251 denosumab Drugs 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- -1 ipilimumab Chemical compound 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 108010093470 monomethyl auristatin E Proteins 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022077341A JP7459168B2 (ja) | 2015-07-02 | 2022-05-10 | ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187878P | 2015-07-02 | 2015-07-02 | |
| US62/187,878 | 2015-07-02 | ||
| US201562264026P | 2015-12-07 | 2015-12-07 | |
| US62/264,026 | 2015-12-07 | ||
| PCT/US2016/040361 WO2017004357A1 (en) | 2015-07-02 | 2016-06-30 | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022077341A Division JP7459168B2 (ja) | 2015-07-02 | 2022-05-10 | ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519831A JP2018519831A (ja) | 2018-07-26 |
| JP2018519831A5 true JP2018519831A5 (enExample) | 2019-08-08 |
| JP7073109B2 JP7073109B2 (ja) | 2022-05-23 |
Family
ID=57609287
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568143A Active JP7073109B2 (ja) | 2015-07-02 | 2016-06-30 | ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法 |
| JP2022077341A Active JP7459168B2 (ja) | 2015-07-02 | 2022-05-10 | ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022077341A Active JP7459168B2 (ja) | 2015-07-02 | 2022-05-10 | ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10758624B2 (enExample) |
| EP (1) | EP3316894A4 (enExample) |
| JP (2) | JP7073109B2 (enExample) |
| CN (2) | CN114224907A (enExample) |
| CA (1) | CA2991052A1 (enExample) |
| WO (1) | WO2017004357A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2972986A1 (en) | 2015-01-16 | 2016-07-21 | City Of Hope | Cell penetrating antibodies |
| US10912790B2 (en) | 2015-04-22 | 2021-02-09 | Mina Therapeutics Limited | C/EBP alpha saRNA compositions and methods of use |
| CN114224907A (zh) * | 2015-07-02 | 2022-03-25 | 希望之城 | 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法 |
| SG11201906728TA (en) | 2017-02-06 | 2019-08-27 | Mpeg La Llc | Multimeric oligonucleotides having decreased kidney clearance |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| WO2019006371A1 (en) * | 2017-06-30 | 2019-01-03 | City Of Hope | COMPOSITIONS AND METHODS FOR MODULATING MACROPHAGE ACTIVITY |
| AU2018330495A1 (en) | 2017-09-08 | 2020-03-26 | Mina Therapeutics Limited | Stabilized hnf4a sarna compositions and methods of use |
| KR20200143428A (ko) * | 2018-04-10 | 2020-12-23 | 락티젠 세러퓨틱스 | P21 유전자 발현을 활성화하는 방법 |
| WO2019241766A1 (en) * | 2018-06-15 | 2019-12-19 | City Of Hope | Oligonucleotide-based proteolysis targeting chimera |
| CN109762042B (zh) * | 2018-09-21 | 2022-04-08 | 河北艾克美冀生物科技有限公司 | 一种治疗癌症的药物、其合成方法和应用 |
| JP2022523226A (ja) * | 2019-03-04 | 2022-04-21 | エムペグ エルエイ リミテッド ライアビリティ カンパニー | 増強された生理活性を有する多量体オリゴヌクレオチド |
| EP4003423A4 (en) * | 2019-07-26 | 2024-03-06 | MiNA Therapeutics Limited | Compositions and methods of using c/ebp alpha sarna |
| KR102433981B1 (ko) * | 2020-12-15 | 2022-08-19 | 대구가톨릭대학교산학협력단 | HIF-1α 및 STAT5 전사인자를 억제하는 합성 디코이 올리고핵산 및 이를 유효성분으로 함유하는 아토피 피부염의 예방 또는 치료용 약학적 조성물 |
| JP2024506042A (ja) * | 2021-02-08 | 2024-02-08 | ラクティゲン セラピューティクス | 多価オリゴヌクレオチド薬剤およびその使用方法 |
| US20250376689A1 (en) * | 2021-08-31 | 2025-12-11 | City Of Hope | Oligonucleotides having 6-thio-2'-deoxyguanosine residues and uses thereof |
| CN114908094B (zh) * | 2022-05-31 | 2024-03-12 | 中山大学 | 一类反义寡核苷酸分子及其在制备治疗恶性肿瘤药物中的应用 |
| WO2024077228A2 (en) * | 2022-10-07 | 2024-04-11 | City Of Hope | Double-stranded oligonucleotides and methods of use |
| EP4627086A2 (en) * | 2022-11-29 | 2025-10-08 | Lonza Sales AG | Methods of using extracellular vesicle-aso targeting stat6 |
| CN118480552B (zh) * | 2024-01-18 | 2024-10-01 | 成都先衍生物技术有限公司 | 一种靶向CEBPA基因表达的saRNA及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| EP0495421B1 (en) | 1991-01-15 | 1996-08-21 | Alcon Laboratories, Inc. | Use of carrageenans in topical ophthalmic compositions |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6867289B1 (en) * | 1998-10-26 | 2005-03-15 | Board Of Regents, The University Of Texas Systems | Thio-modified aptamer synthetic methods and compositions |
| US6159694A (en) | 1999-04-08 | 2000-12-12 | Isis Pharmaceuticals Inc. | Antisense modulation of stat3 expression |
| ITRM20030149A1 (it) * | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| US20070265220A1 (en) * | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| WO2005116268A2 (en) * | 2004-05-27 | 2005-12-08 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health | Differential expression of molecules associated with acute stroke |
| EP1871426B1 (en) * | 2005-04-15 | 2017-06-07 | The Regents of The University of California | Small activating rna molecules and their use |
| AU2007345648A1 (en) | 2007-01-26 | 2008-08-07 | City Of Hope | Methods and compositions for the treatment of cancer or other diseases |
| US8748405B2 (en) * | 2007-01-26 | 2014-06-10 | City Of Hope | Methods and compositions for the treatment of cancer or other diseases |
| US20110250138A1 (en) * | 2007-08-01 | 2011-10-13 | Alnylam Pharmaceuticals, Inc. | Single-stranded and double-stranded oligonucleotides comprising a metal-chelating ligand |
| EP2370582B1 (en) * | 2008-12-04 | 2017-05-10 | CuRNA, Inc. | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
| WO2012128785A1 (en) | 2011-03-22 | 2012-09-27 | City Of Hope | Methods and compositions for the treatment of cancer or other diseases |
| MY163004A (en) | 2011-04-01 | 2017-07-31 | Ionis Pharmaceuticals Inc | Modulation of signal transducer and activator of transcription 3 (stat3) expression |
| WO2014047649A1 (en) * | 2012-09-24 | 2014-03-27 | The Regents Of The University Of California | Methods for arranging and packing nucleic acids for unusual resistance to nucleases and targeted delivery for gene therapy |
| PL2920308T3 (pl) * | 2012-10-31 | 2019-06-28 | Ionis Pharmaceuticals, Inc. | Leczenie nowotworu |
| MX2015013021A (es) * | 2013-03-14 | 2016-07-14 | Nat And Kapodistrian University Of Athens | 5-bromo-indirrubinas. |
| KR102507624B1 (ko) * | 2013-11-22 | 2023-03-09 | 미나 테라퓨틱스 리미티드 | Ｃ/ｅｂｐ 알파 짧은 활성화 ｒｎａ 조성물 및 사용 방법 |
| WO2015077657A2 (en) | 2013-11-22 | 2015-05-28 | City Of Hope | Stat3 inhibitors and uses thereof |
| CN114224907A (zh) | 2015-07-02 | 2022-03-25 | 希望之城 | 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法 |
-
2016
- 2016-06-30 CN CN202111383325.9A patent/CN114224907A/zh active Pending
- 2016-06-30 JP JP2017568143A patent/JP7073109B2/ja active Active
- 2016-06-30 US US15/740,914 patent/US10758624B2/en active Active
- 2016-06-30 CN CN201680047408.1A patent/CN107980001B/zh active Active
- 2016-06-30 EP EP16818778.9A patent/EP3316894A4/en active Pending
- 2016-06-30 CA CA2991052A patent/CA2991052A1/en active Pending
- 2016-06-30 WO PCT/US2016/040361 patent/WO2017004357A1/en not_active Ceased
-
2020
- 2020-07-24 US US16/938,169 patent/US11464865B2/en active Active
-
2022
- 2022-05-10 JP JP2022077341A patent/JP7459168B2/ja active Active
- 2022-07-14 US US17/812,607 patent/US20220401563A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519831A5 (enExample) | ||
| US10149905B2 (en) | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent | |
| AU2017310146B2 (en) | Peptide nucleic acid complex having improved cell permeability and pharmaceutical composition comprising same | |
| TWI761305B (zh) | 抑制Ｈｉｆ２α基因表現之組合物及方法 | |
| CN108779464B (zh) | 使用靶向angpt2和pdgfb的rna复合物治疗血管生成相关性疾病 | |
| JP5559159B2 (ja) | 修飾オリゴヌクレオチドを使用するｈｒｐ−３の阻害 | |
| CN105899663B (zh) | 用于基因表达控制的人工模拟miRNA及其用途 | |
| JP2018530589A5 (enExample) | ||
| CA3120580A1 (en) | Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use | |
| RU2753517C2 (ru) | Антисмысловые олигонуклеотиды к hif-1-альфа | |
| WO2017068791A1 (ja) | 少なくとも１つのバルジ構造を有する核酸複合体 | |
| JP6492014B2 (ja) | 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途 | |
| JP7306653B2 (ja) | 構造強化されたＳ－ＴｕＤを用いた新規がん治療法 | |
| CA3224708A1 (en) | Targeting oncogenic kras with molecular brush-conjugated antisense oligonucleotide | |
| KR101168726B1 (ko) | 암 치료용 약학 조성물 | |
| KR100861278B1 (ko) | 암 치료용 리보핵산 의약 조성물 | |
| US11149271B2 (en) | Method and pharmaceutical composition for treating cancer | |
| CN110870871B (zh) | 用于治疗癌症的方法和药物组合物 | |
| US10548990B2 (en) | Modified siRNA and pharmaceutical composition | |
| EP3974531A1 (en) | Asymmetric sirna inhibiting expression of pd-1 | |
| AU2018101287A4 (en) | Method and pharmaceutical composition for treating cancer | |
| CN101935649B (zh) | 一种抑制Survivin表达的siRNA分子及其应用 | |
| CN117460826A (zh) | 靶向FAP阳性细胞的siRNA缀合物及其药物组合物和应用 | |
| KR20230128690A (ko) | 핵산 복합체를 포함하는 폐암 예방 또는 치료용 조성물 | |
| JP2020070252A (ja) | 腫瘍免疫賦活剤 |